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Alexei Zelenev and colleagues presented an elegant analysis of treatment-as-prevention (TasP) for hepatitis 
C virus (HCV) in people who inject drugs (PWID),1 using a model capturing the dynamics of the injecting-
partnership network, which is superior to the more-common approaches of compartmental modelling 
(omitting network structure) and static network modelling (omitting changes in partnerships over time). 
Their findings regarding the importance of diversity in PWID populations and injecting-partnership 
networks reinforce a recent study2 which used behavioural data from PWID in London, England, to 
parameterise and compare different dynamic network models, and a standard compartmental model, 
regarding the impact of TasP. In this population, where HCV prevalence is 43%, TasP can be highly effective 
but limited information on the detailed characteristics of the injecting-partnership network causes 
uncertainty in the coverage required. 
Zelenev et al.1 emphasise the need for “sufficient coverage” in settings where TasP could be effective. We 
highlight that an intense intervention with relatively high coverage will be cheaper and more effective than 
a less-intensive intervention that is nevertheless “sufficient”.2 This is because transmission is reduced more 
rapidly and therefore fewer courses of treatment are ultimately required to obtain the same reduction in 
prevalence (reducing costs) and fewer cases of illness occur (benefiting health).2 We encourage funders to 
be bold and commit substantial resources initially, rather than providing ‘incremental’ funding and 
requiring evidence of impact before committing further funds. A similar approach to sexually-transmitted 
infections in England in the mid-2000s, informed by modelling,3 which achieved success.4 
Notably, direct comparison of dynamic injecting-partnership network modelling with compartmental 
modelling (which assumes that everyone is constantly connected equally to everyone else) found the latter 
is highly over-optimistic regarding TasP, greatly underestimating the coverage necessary for HCV control.2 
Post-treatment reinfection risk is a key determinant of TasP’s cost-effectiveness; it depends upon whether 
individual patients continue injecting drugs (and whether their injecting practices become safer if so), and 
HCV prevalence in their injecting partners,2 which in turn depends upon the scale and targeting1,2 of TasP 
and other interventions. Since “small-scale trials are suitable only for measuring the individual-level 
[behavioural] component [of reinfection risk]”,2 empirical study of the impact of TasP for HCV in PWID, and 
potential synergies5 of combining with opiate substitution therapy and needle and syringe programmes, 
needs to be done at full scale.6  
Finally, modelling would ideally use realistic dynamic networks, with local population parameters, including 
progression rates,7 to inform appropriate intervention decisions. 
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